Voorbeelden van het gebruik van Salmeterol in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Salmeterol inhibition of CYP3A.
It is possible that Salmeterol gives side effects.
Salmeterol is a long-acting beta-2 agonist.
An immunotoxicity screening study on Salmeterol in rats.
Salmeterol is a long-acting bronchodilator.
Mensen vertalen ook
It contains the active ingredients fluticasone and salmeterol.
Salmeterol medicine to treat asthma.
It contains two active ingredients, salmeterol and fluticasone.
Salmeterol and formoterol are examples of these.
formoterol or salmeterol.
Salmeterol helps open the airways in the lungs.
fluticasone and salmeterol.
Salmeterol inhalation is used to prevent asthma attacks.
Concurrent administration of salmeterol and Genvoya is not recommended.
Salmeterol may increase the risk of asthma-related death.
Concurrent administration of salmeterol with VIRACEPT is not recommended.
Salmeterol for asthma or chronic obstructive pulmonary disease COPD.
Aerivio Spiromax contains two medicines, salmeterol and fluticasone propionate.
Translated Salmeterol is a long-acting Beta2-adrenoreceptor agonist.
Showing prices on products containing Salmeterol as an active ingredient.
Use salmeterol inhalation regularly to get the most benefit.
For pharmacokinetic purposes each component can be considered separately. Salmeterol.
Concomitant use of salmeterol and boosted PREZISTA is not recommended.
unless the benefits outweigh the potentially increased risk of systemic effects of salmeterol treatment.
Do not take Viani If you are allergic(hypersensitive) to salmeterol xinafoate, fluticasone propionate or to the other ingredient Norflurane HFA 134a.
When salmeterol and fluticasone propionate were administered in combination by the inhaled route, the pharmacokinetics of each component were similar to those observed when the drugs were administered separately.
Co-administration with ketoconazole did not increase the elimination half-life of salmeterol or increase salmeterol accumulation with repeat dosing.
statistically significantly faster compared to salmeterol/fluticasone 50/500 microgram.
This may lead to an increase in the incidence of other systemic effects of salmeterol treatment(e.g. prolongation of QTc interval and palpitations) compared with salmeterol or ketoconazole treatment alone see section 4.4.
other potent CYP3A4 inhibitors should therefore be avoided unless the benefits outweigh the potentially increased risk of systemic undesirable effects of salmeterol treatment see section 4.5.